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Abstract
Background: Cervical cancer incidence and mortality rates in Sub-Saharan Africa (SSA) remain high due to several
factors including low levels of uptake of cervical cancer screening. Self-collection of cervicovaginal samples for HPV
DNA testing may be an effective modality that can increase uptake of cervical cancer screening in SSA and hard
to reach populations in developed countries. We investigated whether self-collection of cervicovaginal samples
for HPV DNA tests would be associated with increased uptake of screening compared with clinic based
collection of samples. Furthermore, we compared the quality of samples collected by both approaches for
use in HPV genotyping.
Methods: We conducted a community based randomized trial in a semi-urban district of Abuja, Nigeria with
400 women, aged 30 to 65 years randomized to either hospital-collection or self-collection of cervicovaginal
samples. We compared cervical cancer screening uptake among the 2 groups and evaluated the concentration of
human DNA in the samples by measuring RNase P gene levels using qPCR. High-risk HPV DNA detection and typing
was done using the GP5+/6+ Luminex system.
Results: Most participants in the self-collection arm (93%, 185/200) submitted their samples while only 56%
(113/200) of those invited to the hospital for sample collection attended and were screened during the study
period (p value < 0.001). Human genomic DNA was detected in all but five (1.7%) participants, all of whom
were in the self-collection arm. The prevalence of high-risk HPV in the study population was 10% with types
35, 52 and 18 being the commonest.
Conclusions: Our study shows that self-sampling significantly increased uptake of HPV DNA based test for
cervical cancer screening in this population and the samples collected were adequate for HPV detection and
genotyping. Cervical cancer screening programs that incorporate self-sampling and HPV DNA tests are feasible
and may significantly improve uptake of cervical cancer screening in SSA.
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Background
Cervical cancer is the fourth most common cancer among
women worldwide, with an estimated 528,000 new cases
and 266,000 deaths in 2012 [1]. More than 85% of new
cases occur in low and middle income countries (LMIC)
and the incidence is projected to rise by 5% over the next
10 years [2]. It is the second most frequently diagnosed
cancer and the leading cause of cancer deaths in Sub-
Saharan African (SSA) women [2]. The Age-Standardised
Incidence Rate (ASR) for cervical cancer in Nigeria was
34.5/100,000 population in 2012 [3].
The incidence and mortality of cervical cancer has
declined significantly in developed countries due to
widespread availability and uptake of cervical cancer
screening [4]. These screening programs were initially
based on cervical cytology but HPV DNA based tests
are increasingly used. In contrast, cervical cancer screen-
ing in LMIC has not been so successful due to several
factors including low levels of awareness, cost, cultural
barriers and lack of screening programmes [5–7].
Several approaches have been investigated to provide
cervical cancer screening in LMIC. Cytology based
screening has not been effective therefore other methods
such as visual inspection with acetic acid and HPV DNA
testing are increasingly being evaluated [8, 9]. Studies
have found that women screened for cervical cancer at
least once in their lifetime using HPV DNA testing
significantly reduce their risk of developing advanced
cervical cancers and cervical cancer related deaths [8, 10].
Barriers to uptake of cervical cancer screening in
LMIC such as cost, lack of infrastructure and concerns
about health care workers’ attitudes can be overcome by
using self-collection of cervico-vaginal samples paired
with HPV DNA tests [11]. When combined with an
effective means for sample transportation to the labora-
tory, return of results and prompt treatment, such
screening methods may overcome many of the chal-
lenges associated with cervical cancer screening in LMIC
[12]. Research into cost-effective cervical cancer screen-
ing methods that are based on HPV DNA tests which
involve minimal number of clinic visits are urgently
needed.
In this study, we compared the uptake of home based,
self-collection with clinic based, health professionals’ col-
lection of cervicovaginal samples for HPV DNA tests for
cervical cancer screening in a semi-urban area in Abuja,
Nigeria. We evaluated the quality of the samples collected
to ascertain their utility of the HPV DNA tests and geno-
typed the HPV types found in this study population.
Methods
Setting and participants
We randomly selected Karu out of three semi-urban
districts around Abuja, the capital of Nigeria, that had
relatively heterogeneous populations based on socio-
economic status, easy access to hospitals for health
professionals collected cervicovaginal samples and a
functioning postal system so that women who self-
collect their samples can have the option of mailing it to
our laboratory. Karu had a population of about 205,477
in 2006 [13].
Community engagement
We engaged the Karu community by meeting with the
King of the community and his council members,
explaining the study to them and seeking their permis-
sion to work in the community. After permission was
granted, we met with key religious and opinion leaders,
and organized a meeting with all members of the com-
munity at the King’s palace where we explained the
rationale and methods of the study. We also visited all
the religious and cultural gatherings that took place
within the community during the study period and
extended invitations to participate in the study to all
women between 30 to 65 years of age.
Enrollment and randomization
Between February 2014 and May 2014, all women inter-
ested in the study were invited to meet the research
team at the King’s palace which is centrally located
within the community. Inclusion criteria were women
aged between 30 and 65 years, living or working in Karu
who do not plan to move out of the community over the
next 6 months. We excluded women who were preg-
nant, planning to relocate within six months, HIV posi-
tive, had unexplained cervical bleeding, history of
hysterectomy, mental illness or cervical cancer from the
study. All women provided written informed consent.
After consenting, all the women were given health
education on cervical cancer, its risk factors, the research
project, sampling procedure and randomization. We
generated a random numbers’ list and created 2 groups.
We assigned the 200 odd numbers on the list to the
self-sampling group and the 200 even numbers to the
hospital-based sampling group. Women were sequen-
tially assigned to either the hospital-collection group or
the self-collection group as they enrolled and consented
to participate in the study. Women randomized to self-
sample were given the self-sampling kit and instructions
on how to use it while those assigned to the hospital
group were given appointments for the clinic.
Participants were not blinded with regards to the
intervention they received because this was not feasible.
Study procedure
All the women enrolled in the study were administered a
questionnaire in a language they understood by a trained
research nurse. The questionnaire asked questions about
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socio-demographics, sexual health and behaviour, obstet-
rics and gynaecology history, vaginal health, as well as
cervical cancer screening history. Measures incorporated
in this study were selected from the PhenX Toolkit
version July 31 2013, Ver 5.5.
Sample collection
Women in the hospital-collected group had cervicovagi-
nal samples collected at the National Hospital Abuja,
Cervical Cancer Screening Clinic by trained nurses using
a dry flocked swab (Copan Diagnostics INC CA USA).
Participants in the self-collection group used dry
flocked swabs to collect cervicovaginal samples at home
and inserted them into pre-stamped envelopes that we
provided. They had the option to mail the envelope
through the post-office, or drop the envelopes off at
designated collection points within the community or at
the National Hospital, Abuja, Nigeria.
We returned results of HPV DNA tests to participants’
via text messages on their cell phones and invited those
who were positive for hrHPV to return for treatment
and follow up.
Laboratory analyses
The swabs were stored at −80°C at the Institute of
Human Virology Nigeria Bioreprository prior to ana-
lyses. We performed the laboratory analysis at DDL
Diagnostic Laboratory, Rijswijk, the Netherlands. Mate-
rials from swab specimens were suspended in 3mL of
phosphate buffered saline (PBS). DNA was extracted
from 750μl using the EasyMAG NucliSens extraction
platform (BioMérieux, Boxtel, the Netherlands) [14].
The extracted DNA was eluted in 100μl of wash buffer 3.
Each DNA extraction run contained positive and negative
controls to monitor the extraction procedure. HPV detec-
tion and typing was performed using GP5+/6+ PCR-EIA
system with LMNX genotyping according to the manufac-
turer’s instructions (LMNX Genotyping kit HPV GP HR,
Labo Bio-medical Products, Rijswijk, the Netherlands)
[15]. A 10μl aliquot of extracted DNA was used for each
GP5+/6+ PCR. Quantitative real time PCR was performed
to measure the human DNA concentration through detec-
tion of a 65bp fragment from the RNase P gene. Detection
of the RNase P gene was used as a quality control measure
for sample adequacy [16]. Five microliter of extracted
DNA was added to 20 μl of PCR mastermix and amplifi-
cation was performed on a Bio-Rad CFX96 real time PCR
detection system (Bio-Rad Inc. Berkeley, CA, USA).
Quantification of the amount of RNase P copies present
in each sample was done by comparing the observed
quantification cycle (Cq) of the sample to the Cq values
of the standard curve with known concentrations of
human DNA (i.e., 300000, 30000, 3000, 300 and 100
haploid genomic equivalent (GEQ) copies/PCR).
Positive and negative PCR controls were used in each run.
Samples were considered invalid if they had a negative
RNase P result (Cq values of >40).
Outcome measures
The primary outcome measure was uptake of cervical
cancer screening using HPV DNA tests which we de-
fined as the proportion of women who completed the
screening procedure out of all women enrolled in each
group during the study period. The study period lasted
for one month after enrollments were completed. We
also evaluated secondary outcomes including predictors
of acceptance of screening and preference for self-
sampling. We tested each swab for presence and type of
high risk HPV and concentration of human DNA.
Data analysis
We conducted intention-to-treat analysis. Women who
responded to either method of screening (self-collection
or hospital-collection) were considered as a positive result
of the strategy to which they had been randomized regard-
less of which method they finally used for screening.
Study data were collected and managed using REDCap
electronic data capture tools hosted at the Institute of
Human Virology Nigeria [17]. We used logical checks
and validation protocols to ensure high quality data.
Statistical analysis of data obtained was performed using
STATA version 12 software (StataCorp, College Station,
Texas, USA). Means and standard deviations were used
to describe continuous variables while categorical vari-
ables were expressed in terms of frequencies and pro-
portions. We computed socioeconomic status using
Principal Component Analysis of Wealth Index data as
described [18].
Logistic regression models were used to evaluate pre-
dictors of screening uptake including baseline character-
istics and prior knowledge of cervical cancer. Odds
ratios (OR) and 95% confidence intervals (CI) were gen-
erated. An association was statistically significant if the
p-value was less than or equal to 0.05. We used differ-
ences in mean human DNA concentrations to determine
efficiency of swabs collected using student-t tests.
Samples with absent RNase P (Cq values >40) were
excluded from the data analysis.
We obtained ethical approval for the study from
the National Hospital Abuja, Health Research Ethics
Committee (Approval number NHA/EC/238/20).
Role of the funding source
The funder had no role in study design, data collection,
data analysis, data interpretation, or writing of the
report. The corresponding author had full access to all
data used in this study and had final responsibility on
the decision to submit for publication.
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Results
We enrolled 400 women who consented into the study.
Figure 1 shows the study design and the women who
participated in the study. The mean (SD) age of the
women was 40.8 (1.3) years. Most participants (337,
84.3%) were in the age group 30–49 years, 328 (82%)
were married and 331 (82.8%) were Christians. About
half (199, 49.8%) of the participants had attended tertiary
level of education and 212 (53%) belonged to the middle
socioeconomic class. Some 47% (188/400) of women
enrolled in the study had heard of cervical cancer
(Table 1). Of this number, 45% heard about the disease
from the television, 22.5% from personal communica-
tions, 17.6% from a health care practitioner, 17.1% from
other forms of mass media and 8% from church aware-
ness programs. Most of the participants, 98.8% (395/
400) had never been screened for cervical cancer and
the reasons for this included lack of access to screening
services (49.7%), lack of time (8.7%), financial constraints
(7.2%), lack of knowledge of screening (6.2%) and long
hospital waiting times (3.6%).
Overall 75% (298/400) of the women completed cer-
vical cancer screening within the study period. Most
of the women in self-collection arm, 93% (185/200),
were screened while 56% (113/200) of those invited
to hospital completed screening during the study
period (p < 0.001). All 185 (100%) self-collected swabs
were submitted within 24 h of cervicovaginal sample
Fig. 1 Flow chart showing enrolment, randomization and testing results
Modibbo et al. Infectious Agents and Cancer  (2017) 12:11 Page 4 of 9
collection in a designated collection box in the commu-
nity. Most of the women in the self-collection arm of
the study chose this option because they found it con-
venient (84.3%, 156/185) while 10.3% (19/185) chose this
option because they did not trust the postal service to
deliver the swabs in a safe and timely manner. Most of
these women (95.2%, 177/185) found the self-sampling
device easy to use while 4.3% (8/185) found it
difficult to use and 83.2% (154/185) would prefer self-
sampling as a future screening option than hospital-
sampling (Table 2). There was no association between
age, religion, marital status, awareness of cervical can-
cer, education, socio-economic status, and uptake of
screening (Table 3).
Table 1 Baseline Characteristics for Women Enrolled in Study N = 400
Hospital-collected (N = 200) Self-collected (N = 200) All (N = 400) P value
Mean age in years (SD) 40.3(0.99) 41.3(1.06) 40.8(1.29)
Age in years 0.132
30–39 103(51.5%) 82(41%) 185(46.3%)
40–49 67(33.5%) 85(42.5%) 152(38%)
50–59 26(13%) 31(15.5%) 57(14.3%)
60 and above 4(2%) 2(1%) 6(1.5%)
Religion 0.597
Christianity 163(81.5%) 168(84%) 331(82.8%)
Islam 37(18.5%) 32(16%) 69(17.3%)
Marital status 0.152
Married 158(79%) 170(85%) 328(82%)
Not Married 42(21%) 30(15%) 72(18%)
Educational status 0.592
No formal schooling 19(9.5%) 16(8%) 35(8.8%)
Primary education 38(19%) 30(15%) 68(17%)
Secondary education 35(17.5%) 41(20.5%) 76(19%)
Tertiary education 96(48%) 103(51.5%) 199(49.8%)
Socioeconomic status 0.484
Upper class 14(7%) 12(6%) 26(6.5%)
Middle class 100(50%) 112(56%) 212(53%)
Lower class 86(43%) 76(38%) 162(40.5%)
Heard of cervical cancer 0.483
Yes 90(45%) 98(49%) 188(47%)
No 110(55%) 102(51%) 212(53%)
Ever screened for cervical cancer 1.000
Yes 2(1%) 3(1.5%) 5(1.3%)
No 198(99%) 197(98.5%) 395(98.8%)
No of sexual partners in the last 12months 0.286
1 163(81.5%) 169(84.5%) 395(98.8%)
2–3 5(2.5%) 2(1%) 7(1.8%)
≥ 4 0(0%) 2(1%) 2(0.5%)
Unknown 32(16%) 27(13.5%) 59(14.8%)
Age at sex initiation 0.150
< 16 27(13.5%) 15(7.5%) 42(10.5%)
16–19 66(33%) 61(30.5%) 127(31.8%)
≥ 20 88(44%) 106(53%) 194(48.5%)
Unknown 19(9.5%) 18(9%) 37(9.3%)
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The median (IQR) of DNA concentrations from the
self-collected (n = 185) and hospital-collected (n = 113)
swabs were 10.5 (2.81–27.68) and 6.6 (2.37–11.80)
respectively. There was a significant difference in DNA
concentration between self-collected and hospital-
collected samples (p = 0.003).
Of the 298 samples received, 29 (10%) were positive
for hrHPV. The prevalence of hrHPV infection among
women in the self-collection group was 8.9% (19/185)
while it was 10.3% (10/113) among women in the health
professionals’ collection group. These were not statisti-
cally significantly different (p = 0.84). The prevalence of
hrHPV infections by age groups were 8.5% for women in
the 30–39 years’ age group, 12.4% for those in 40–49
years’ age group and 6.4% for those aged 50 years and
above. Among the 29 women positive for hrHPV, the
mean (SD) age at sexual debut was 20.2 (6.4) years com-
pared with 20.3 (4.3) years among the hrHPV negative
women. There were no associations between hrHPV
positivity and either socio-economic status (p = 0.29) or
obesity (p = 0.69). Age, religion, marital status, hormonal
contraceptive use, and douching were not significantly
associated with risk of hrHPV infection. None of the
hrHPV positive women smoked cigarettes and 89.7%
(26/29) reported having only one sexual partner in the
last 12 months.
Most of the women with hrHPV infection (24, 82.8%)
had single hrHPV infections spanning 11 types (Fig. 2),
3 (10.3%) had multiple hrHPV infections viz. 16 and 18,
35 and 56, and 35, 56 and 58 while 2 infections (6.1%)
were not classifiable and were designated “Type X”
(Fig. 2). Types 35 (18.2%), 52 (18.2%) and 18 (12.2%)
were the most prevalent hrHPV types in this study.
Types 16 was found in only one (3.0%) participant.
Discussion
In this study, we found that significantly higher propor-
tion of women in the self-collection group completed
HPV DNA based tests for cervical cancer screening
compared to women invited to hospital for health pro-
fessionals’ collections of samples. Our results show that
self-collection is a viable method of increasing cervical
cancer screening uptake in LMIC. Similarly high re-
sponse rates for self-sampling have been reported in
Uganda and Cameroun [19, 20]. In developed countries
where organized screening programs are available, self-
sampling has been shown to improve cervical cancer
screening rates among women who fail to attend regular
screening [21]. Although women in the self-sampling
Table 2 Operational Aspects of Cervicovaginal Self-collection
N = 185
Variable n % 95% CI
Reason for preference of collection box
Convenient 156 84.3 79.6;90.0
Distrust of postal service 19 10.3 5.9;14.6
Privacy 5 2.7 0.4;5.0
Cultural reasons 5 2.7 0.4;5.0
Sample device
Easy to use 177 95.7 92.1;98.3
Difficult to use 8 4.3 1.4;7.2
Future screening preference
Self-sampling 154 83.2 77.8;88.6
Comfortable 134/154 87.0
Private 10/154 6.5
Less embarrassing 5/154 3.3
To ensure the right sample is taken 3/154 2.0
Financially convenient 1/154 0.6
Sense of independence 1/154 0.6
Hospital-sampling 17 9.2 5.0;13.4
To ensure right sample is taken 13/17 76.5
Comfortable 3/17 17.7
Better option 1/17 5.8
No Preference 14 7.6 3.8;11.4
CI Confidence intervals
Table 3 Predictors for Screening Uptake
Predictor Adjusted ORa 95% CIa P valuea
Age
30–39 Reference
40–49 1.40 0.80–2.44 0.237
50 above 1.08 0.53–2.31 0.835
Religion
Christianity Reference
Islam 1.49 0.76–2.93 0.247
Marital status
Not Married Reference
Married 1.15 0.62–2.14 0.651
Education
No formal schooling Reference
Formal schooling 1.06 0.54–2.20 0.861
Socioeconomic status
Lower class Reference
Middle class 1.14 0.68–1.91 0.627
Upper class 1.07 0.38–2.99 0.894
Cervical cancer awareness
No Reference
Yes 0.76 0.48–1.20 0.234
OR Odds Ratio, CI Confidence intervals
aOR, 95% CI and P values obtained from logistic models adjusting for method
of sample collection
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arm of this study had several options for sending their
samples to the lab, all participants chose to leave their
samples at designated collection points in the commu-
nity. This result was not unexpected given the poor
quality of mail services in Nigeria. Concerns about send-
ing such an intimate biological sample through the
postal system may also have influenced this choice.
Majority of the women in the self-sampling group
would prefer to repeat self-sampling at their next
screening visit instead of having to visit a hospital. This
is similar to findings from other self-sampling studies in
low and middle income countries [19, 22]. In Kenya,
lack of transportation, cost and long hospital queues
were reported as deterrents to hospital-based screening
[23]. Majority of participants in this study identified lack
of cervical cancer screening services in healthcare facil-
ities as the reason why they had not participated in
screening in the past. Given the high morbidity and
mortality of cervical cancer, and the availability of
screening options, research into methods of implemen-
tation of cervical cancer screening that would have high
levels of uptake in the community is urgently needed.
Other important barriers to cervical cancer screening in
Nigerian have been previously published [11].
None of the characteristics of participants evaluated
were found to be significantly associated with screening
uptake in this population. This finding strengthens the
argument that the major deterrent to cervical cancer
screening in LMIC is non-availability. Most SSA coun-
tries lack of human resources and infrastructure re-
quired for establishment of systematic cervical cancer
screening, and their health budgets need to address
competing needs from infectious diseases [24]. To be
successful, screening programs in SSA should to be based
on more abundant cadre of health professionals like
nurses, midwives and community health workers [9].
Almost all our participants found the dry flocked swab
easy to use. This finding is comparable to that from studies
in other SSA countries where similar collection device was
used [20, 25, 26]. Previous studies have documented that
women were concerned about their ability to successfully
sample themselves [19, 27]. Our study shows that this con-
cern can be assuaged by properly educating the women on
how to perform the procedure prior to collection [20].
All women in the self-sampling group returned their
swabs within 24 h of collection. We found that most
samples except five from self-collection group had
adequate DNA samples based on RNase P levels. The
use of RNase P to check adequacy of human genomic
DNA present in biological samples is well established
[16]. This finding reinforces the evidence that women
can be educated to collect samples of adequate quality.
Studies of self-collected samples that are processed after
longer intervals between collection and analyses should
be conducted in order to evaluate whether this approach
is robust in the health care settings.
The prevalence of hrHPV infection in this study is
similar to findings from our previous studies of women
who presented for screening at hospitals in Abuja,
Nigeria [28, 29]. This suggests that the population point
prevalence of hrHPV in Nigeria is 10%. We detected
eleven types of hrHPV in this study with types 35, 52
and 18 predominating and constituting almost 50% of all
types detected. HPV 35 has been reported as the
Fig. 2 High risk HPV distribution based on clinically validated GP5+/6+ assay
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commonest type found in women with normal cytology
in Sub-Saharan Africa [30], and studies conducted in
Benin Republic, Guinea, Mozambique and Abuja have
all published similar findings [28, 31–33]. The finding of
HPV 52 and 18 being among the most prevalent types is
consistent with other Nigerian studies [34, 35]. These
three types of HPV are among eight that account for
86% of cervical cancers worldwide [36]. Although HPV
16/18 infections account for majority of the disease
worldwide, the contributions of HPV 16 to invasive cer-
vical cancer from Sub-Saharan Africa and in particular
West Africa is among the lowest globally [36, 37].
A limitation of our study is the use of interviewer
administered questionnaires which may have skewed
responses to some of the sensitive questions towards what
was perceived to be more socially acceptable, however
studies have shown that the influence of biased responses
are minor and do not affect overall results [38, 39]. The
demographic characteristics of our participants also dif-
fers from that of the general Nigeria population and this
may limit the generalizability of our results [40]. Some
members of the community may have opted not to
respond to the invitations to participate in the study and
we cannot rule out healthy volunteer bias.
Conclusions
Our findings further strengthens the evidence that cervi-
covaginal self-sampling is an acceptable modality that
can lead to a substantial increase in the proportion of
women who are screened for cervical cancer in LMIC.
The quality of cervicovaginal samples collected by self-
sampling is adequate for HPV DNA detection and typing.
This justifies further studies that integrate this modality
into cervical cancer screening programs in LMIC.
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